BridgeBio Oncology Therapeutics, Inc. (BBOT) — Defensive Interval Ratio
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Defensive Interval Ratio of 1685 days as of March 2026. Defensive assets of $199.76 Million (cash $-, short-term investments $199.62 Million, receivables $146.00K) cover 1685 days of daily cash needs of $118.52K/day. See working capital position of BridgeBio Oncology Therapeutics, Inc. to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
BridgeBio Oncology Therapeutics, Inc. Defensive Interval Ratio (2023–2025)
This chart shows how BridgeBio Oncology Therapeutics, Inc.'s Defensive Interval Ratio has evolved across 3 annual periods from 2023 to 2025. As of March 2026, the ratio stands at 1685 days, meaning defensive assets of $199.76 Million can fund 1685 days of operations without new revenue. See BridgeBio Oncology Therapeutics, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below presents the year-by-year Defensive Interval Ratio for BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025, covering 3 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see market cap of BridgeBio Oncology Therapeutics, Inc..
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 543 days | $52.16 Million | $96.00K/day | $- | $51.77 Million | ▼ -242342 days |
| 2024 | 242886 days | $124.78 Million | $513.74/day | $- | $124.78 Million | ▲ +242886 days |
| 2023 | 0 days | $0.00 | $1.09K/day | $- | $0.00 | — |